

Human PD-1/LAG-3 (Luc) Jurkat Reporter Cell


Catalog No.	Size
SCJUR-STF063	$2 \times (1 \text{ vial contains } \sim 5 \times 10^6 \text{ cells})$

• Description

The Human PD-1/LAG-3 (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptors full length human PD-1 (Gene ID: 5133) and LAG-3 (Gene ID: 3902), which can use to evaluate the synergistic effect of anti-human PD-1 and anti-human LAG-3 antibody. When co-cultured with target cells expressing human PD-L1 and MHCII, the PD-1/PD-L1 and LAG-3/MHCII interactions inhibit TCR signaling and NFAT-mediated luminescence. Blocking the PD-1/PD-L1 and LAG-3/MHCII interactions by the stimultaneous addition of anti-PD-1 or anti-PD-L1 and anti-LAG-3 antibodies release the inhibitory signals and result in TCR activation and NFAT-mediated luminescence.

• Application

• Screen for anti-human PD-1 or/and anti-human LAG-3 antibody.



• Cell Line Profile

Cell line	Human PD-1/LAG-3 (Luc) Jurkat Reporter Cell	
Host Cell	Jurkat	
Property	Suspension	
Complete Growth Medium	RPMI-1640 + 10% FBS	
Selection Marker	Hygromycin (20 μg/mL) + Puromycin (5 μg/mL)	
Incubation	37°C with 5% CO ₂	
Doubling Time	16-20 hours	
Transduction Technique	Lentivirus	



• Materials Required for Cell Culture

- RPMI Medium 1640 (Gibco, Cat.No.11875-093)
- Fetal bovine serum (CellMax, Cat.No.SA211.02)
- Puromycin (InvivoGen, Cat.No.ant-pr-5b)
- Hygromycin B (Invitrogen, Cat.No.10687010)
- Complete Growth Medium: RPMI-1640 + 10% FBS
- Culture Medium: RPMI-1640 + 10% FBS, Hygromycin (20 μg/mL), Puromycin (5 μg/mL)
- Freeze Medium: 90% FBS, 10% (V/V) DMSO
- T-75 Culture flask (Corning, 430641)
- Cryogenic storage vials (SARSTEDT, 72.379.007)
- Thermostat water bath
- Centrifuge
- Luna cell counter (Logos Biosystems, LUNA-II)
- CO₂ Incubator (Thermo, 3111)
- Biological Safety Cabinet (Thermo, 1389)

• Recovery

- 1. Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the cap out of the water. Thawing should be rapid (approximately 5 minutes).
- 2. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by spraying with 70% ethanol. All the operations from this point on should be carried out under strict aseptic conditions.
- 3. Transfer the vial contents to a centrifuge tube containing 4.0 mL complete growth medium.
- 4. Count viable cells and spin at approximately 1000 rpm for 5 minutes.
- Discard the supernatant and resuspend the cell pellet in an appropriate amount of fresh complete growth medium.
 Adjust the cell density of the suspension to 1×10⁶ viable cells/mL and transfer cells to an appropriate size vessel.
- 6. Incubate at 37°C with 5% CO₂ incubator.



• Subculture

Adjust the cell density at 2×10^5 -5 $\times 10^5$ viable cells/mL by the addition of fresh culture medium or replacement of culture medium. Do not allow the cell density to exceed 3×10^6 cells/mL. T-75 flasks are recommended for subculturing.

• **Medium Renewal:** Add fresh culture medium every 3 to 4 days (depending on cell density)

Cryopreservation

- 1. Count viable cells and harvest the cell suspension.
- 2. Centrifuge at 1000 rpm for 5 min at RT and resuspend cells in freezing medium to a concentration of 5×10^6 to 1×10^7 cells/mL.
- 3. Aliquot into cryogenic storage vials. Place vials in a programmable cooler or an insulated box placed in a -80°C freezer overnight, then transferring to liquid nitrogen storage.

• Storage

- **Product format:** Frozen
- Storage conditions: Liquid nitrogen immediately upon receipt



• Receptor Assay




Fig1. Co-expression analysis of human PD-1 and LAG-3 on Human PD-1/LAG-3 (Luc) Jurkat Reporter Cell by FACS. Cell surface staining was performed on Human PD-1/LAG-3 (Luc) Jurkat Reporter Cell or negative control cell using FITC-labeled anti-human PD-1 antibody and APC-labeled anti-human LAG-3 antibody.

Synergistic analysis of Anti-human PD-1 and

• Application




Fig2. Analysis of the synergistic effect for anti-human PD-1 and anti-human LAG-3 antibody (RLU).

Conc.Antibody (µg/mL)

10

100

0.1

0.001

0.01

This reporter cell was co-incubated with serial dilutions of anti-human PD-1 plus anti-human LAG-3 antibody in the presence of target cells expressing human PD-L1 and MHCII. The EC50 was approximately $0.58 \, \mu \text{g/mL}$.



Synergistic analysis of Anti-human PD-1 and Anti-human LAG-3 Antibody (FOLD) Anti-human LAG-3 Antibody Anti-human PD-1 Antibody Anti-human PD-1+Anti-human LAG-3 Antibody 400.001 O.01 O.01 Conc.Antibody (µg/mL)

Fig3. Analysis of the synergistic effect for anti-human PD-1 and anti-human LAG-3 antibody (FOLD).

This reporter cell was co-incubated with serial dilutions of anti-human PD-1 plus anti-human LAG-3 antibody in the presence of target cells expressing human PD-L1 and MHCII. The max induction fold was approximately

Passage Stability




Fig4. Passage stability analysis of receptors expression by FACS. Flow cytometry surface staining of human PD-1 and LAG-3 on Human PD-1/LAG-3 (Luc) Jurkat Reporter Cell demonstrates consistent mean fluorescent intensity across passage 8-25. (A) Human PD-1 expression analysis. (B) Human LAG-3 expression analysis.






Fig5. Passage stability analysis by Signaling Bioassay. The continuously growing Human PD-1/LAG-3 Jurkat Reporter Cell was stimulated with serial dilutions of anti-human PD-1 plus anti-human LAG-3 antibody in the presence of target cells expressing PD-L1 and MHCII. Anti-human PD-1 plus anti-human LAG-3 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 8-25.

• License Disclosure

This reporter cell is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this reporter cell available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this reporter cell in any way. Inappropriate use or distribution of this reporter cell will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this reporter cell for any particular use, and does not accept any liability in connection with the handling or use of this reporter cell.

Related Products

<u>Products</u>	<u>Cat.No.</u>
Human PD-1 (Luc) Jurkat Reporter Cell Development Service	SCJUR-STF064
Human LAG-3 (Luc) Jurkat Reporter Cell Development Service	SCJUR-STF065
Human TIGIT (Luc) Jurkat Reporter Cell Development Service	SCJUR-STF066